Pence’s Obamacare stance mirrors Hoosiers’ views
A new survey shows Hoosiers don’t like the Affordable Care Act, most would like to see it repealed, and by a nearly 2-to-1 margin, they support Pence’s handling of the question of expanding Medicaid.
A new survey shows Hoosiers don’t like the Affordable Care Act, most would like to see it repealed, and by a nearly 2-to-1 margin, they support Pence’s handling of the question of expanding Medicaid.
The state insurance department said Wednesday morning that to do so would “create logistical chaos” and “destabilize” Indiana’s individual health insurance market.
Pence wants to expand Medicaid coverage using some form of the Healthy Indiana Plan, which currently provides insurance to about 40,000 Hoosiers who agree to make monthly contributions to health savings accounts. The Obama administration has questioned that feature of the program.
At 1.3 million square feet, the new hospital has plenty of room to display art, most of which was purchased with contributions from donors. The hospital is set to open Dec. 7.
Indiana University Health and Franciscan Alliance saw key parts of their businesses deteriorate sharply, according to new financial reports released by the hospital systems, causing each to slash more than 900 positions.
It’s no secret the growth of the U.S. economy slowed in the 2000s after the go-go decade preceding it. But the U.S. health care system—hospitals, doctors, drug companies, device makers and health insurers—apparently didn’t get that memo.
From the spiraling wooden sculpture suspended from the ceiling in the main concourse to the vegetable garden on the roof, the brand-new Eskenazi Hospital keeps you wondering what you will see around the next corner.
The Zionsville-based firm said it will spend $1.4 million to lease and equip a 16,626-square-foot headquarters facility at Northwest Technology Park to allow for the expansion.
The state’s Division of Disability and Rehabilitative Services ordered an immediate transfer of the residents to other providers Nov. 11. The state recently cited the facility for violations regarding infection control and other problems.
Republicans renewed an assault on President Barack Obama’s health care overhaul and his credibility on Friday as they pushed toward House passage of a measure to let insurers keep selling health coverage that falls short of the law’s strict standards.
The Insurance Forum, an independent newsletter based in central Indiana and read by industry leaders and consumer advocates across the continent, has placed its last issue in the mail.
Chief Deputy Insurance Commissioner Logan Harrison says the Department of Insurance doesn't yet know whether state regulators have the legal authority to approve reversals.
The messy rollout of the insurance exchanges has made it hard for carriers to figure out what business will be like in 2014.
Bowing to pressure, President Barack Obama on Thursday announced changes to his health care law to give insurance companies the option to keep offering consumers plans that would otherwise be canceled.
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
The administration says fewer than 27,000 people managed to enroll for health insurance last month in the 36 states relying on the problem-filled federal website for President Barack Obama’s overhaul.
Eli Lilly and Co. and Pfizer Inc., which are both suffering through some of the largest patent cliffs in the industry, will split any future costs and profits of an osteoarthritis drug that has stalled in clinical testing.
New convention prospects are talking to the city’s marketing agency after passage of the city’s expanded smoking ordinance last year.
Testosterone replacement drugs, a $1.6 billion market for Eli Lilly and Co. and others, boosted the odds of having a heart attack, stroke or dying by 29 percent in one of the first studies weighing the therapy's cardiovascular risks.
Indianapolis-based Eli Lilly and Co., Bayer AG and Boehringer Ingelheim GmbH are among companies that may consider an offer if the Swiss drugmaker proceeds with the animal-health sale.